SEC Form 4 · accession 0001193210-26-000025
Jazz Pharmaceuticals plc · JAZZ
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Bruce C Cozadd
Director
Period of report
Aug 31, 2026
Accepted (ET)
Sep 2, 2026 · 5:03 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001232524
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF2 | Aug 31, 2026 | F | 10 | $244.064 | D | 359,084 | D | |
| Ordinary Shares | Aug 31, 2026 | F | 1,209 | $241.3899 | D | 357,875 | D | |
| Ordinary Shares | Sep 1, 2026 | S | 6,000 | $250.13 | D | 351,875 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units.
- F2Includes the November 3, 2025 disposition of 3,193 shares for the withholding of restricted stock units by the Issuer to satisfy FICA taxes arising from the Reporting Person being retirement eligible which was previously inadvertently not reported; not an open market transaction.
- F3This transaction was made pursuant to a plan adopted by the reporting person on November 26, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person.